PHGE Insider Trading
Insider Ownership Percentage: 21.80%
Insider Buying (Last 12 Months): $0.00
Insider Selling (Last 12 Months): $4,900,000.00
BiomX Share Price & Price History
Current Price: $5.04
Price Change: ▼ Price Decrease of -0.19 (-3.63%)
As of 03/18/2026 05:10 PM ET
BiomX Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 3/17/2026 | Reuven Yeganeh | Director | Sell | 530,000 | $5.00 | $2,650,000.00 | | |
| 3/16/2026 | Reuven Yeganeh | Director | Sell | 450,000 | $5.00 | $2,250,000.00 | | |
| 5/15/2024 | Israel Biofund Gp Limi Orbimed | Major Shareholder | Sell | 128 | $72.20 | $9,241.60 | 72,492 | |
| 11/29/2023 | Assaf Oron | insider | Sell | 574 | $7.03 | $4,035.22 | | |
| 5/22/2023 | Assaf Oron | Insider | Buy | 16 | $51.30 | $820.80 | 57 | |
BiomX Institutional Trading History
| Reporting Date | Hedge Fund | Shares Held | Market Value | % of Portfolio | Quarterly Change in Shares | Ownership in Company | Details |
|---|
| 2/18/2026 | Ikarian Capital LLC | 19,473 | $36K | 0.0% | -95.0% | 1.225% |  |
| 2/13/2026 | Nantahala Capital Management LLC | 114,795 | $0.22M | 0.0% | -95.4% | 7.220% |  |
| 11/17/2025 | Alyeska Investment Group L.P. | 1,590,738 | $0.84M | 0.0% | N/A | 5.990% |  |
| 11/17/2025 | Citadel Advisors LLC | 161,781 | $85K | 0.0% | N/A | 0.609% |  |
| 11/17/2025 | Boothbay Fund Management LLC | 104,463 | $55K | 0.0% | -56.0% | 0.393% |  |
| 11/14/2025 | ADAR1 Capital Management LLC | 77,656 | $41K | 0.0% | -74.1% | 0.292% |  |
| 8/12/2025 | Warberg Asset Management LLC | 80,000 | $36K | 0.0% | -19.7% | 0.306% |  |
| 5/16/2025 | Allostery Investments LP | 940,629 | $0.52M | 0.8% | +46.1% | 3.763% |  |
| 5/16/2025 | Alyeska Investment Group L.P. | 1,590,738 | $0.88M | 0.0% | +83.8% | 6.364% |  |
| 5/16/2025 | ADAR1 Capital Management LLC | 299,598 | $0.17M | 0.0% | N/A | 1.199% |  |
| 5/15/2025 | Nantahala Capital Management LLC | 2,493,309 | $1.39M | 0.1% | +44.1% | 9.975% |  |
| 5/9/2025 | Warberg Asset Management LLC | 99,616 | $55K | 0.0% | N/A | 0.399% |  |
| 5/6/2025 | AIGH Capital Management LLC | 1,566,944 | $0.87M | 0.4% | +81.1% | 6.269% |  |
| 2/17/2025 | Alyeska Investment Group L.P. | 865,400 | $0.63M | 0.0% | N/A | 4.761% |  |
| 2/17/2025 | Allostery Investments LP | 643,833 | $0.47M | 0.5% | N/A | 3.542% |  |
| 2/14/2025 | Heights Capital Management Inc. | 258,492 | $0.19M | 0.1% | -56.1% | 1.422% |  |
| 2/14/2025 | Johnson & Johnson | 96,866 | $71K | 0.0% | -49.6% | 0.533% |  |
| 2/12/2025 | JPMorgan Chase & Co. | 429,990 | $0.31M | 0.0% | N/A | 2.366% |  |
| 11/19/2024 | Barclays PLC | 25,000 | $26K | 0.0% | -90.0% | 0.138% |  |
| 11/15/2024 | Barclays PLC | 25,000 | $26K | 0.0% | -90.0% | 0.140% |  |
| 11/15/2024 | Ikarian Capital LLC | 893,000 | $0.91M | 0.1% | N/A | 4.990% |  |
| 11/14/2024 | Johnson & Johnson | 192,321 | $0.20M | 0.0% | -90.0% | 1.075% |  |
| 11/7/2024 | 8VC GP I LLC | 108,621 | $0.11M | 0.2% | -90.0% | 0.607% |  |
| 5/17/2024 | Ikarian Capital LLC | 10,817,327 | $4.87M | 0.5% | N/A | 19.590% |  |
| 5/10/2024 | Johnson & Johnson | 1,923,201 | $0.87M | 0.0% | -9.9% | 3.483% |  |
| 2/12/2024 | MMCAP International Inc. SPC | 96,805 | $26K | 0.0% | -81.1% | 0.211% |  |
| 2/12/2024 | 8VC GP I LLC | 1,086,191 | $0.30M | 0.3% | N/A | 2.362% |  |
| 11/3/2022 | Royce & Associates LP | 158,655 | $54K | 0.0% | -51.7% | 0.529% |  |
| 5/5/2022 | Royce & Associates LP | 320,655 | $0.62M | 0.0% | +200.5% | 1.077% |  |
| 2/7/2022 | Royce & Associates LP | 106,696 | $0.17M | 0.0% | -52.7% | 0.373% |  |
Data available starting January 2016
BiomX Inc., a clinical-stage microbiome company, develops products using natural and engineered phage technologies designed to target and kill specific harmful bacteria. It targets bacteria that affect the appearance of skin, as well as chronic diseases, such as inflammatory bowel diseases (IBD), primary sclerosing cholangitis (PSC), cystic fibrosis (CF), atopic dermatitis, and colorectal cancer (CRC). It is developing BX004, a phage therapy for CF patients with chronic Pseudomonas aeruginosa respiratory infections that is in Phase 1b/2a clinical trials. The company's pipeline products also include BX005, a topical phage cocktail, which is in Phase 1/2 clinical study that targets Staphylococcus aureus (S. aureus), a bacteria associated with the manifestation of the disease. In addition, the company engages in the provision of colorectal cancer program that utilizes engineered phage with various payloads, which are administered intravenously to target Fusobacterium nucleatum bacteria residing within the tumor microenvironment. BiomX Inc. was founded in 2015 and is headquartered in Ness Ziona, Israel.
Read More on BiomX
Volume
52,934 shs
Average Volume
76,315 shs
Market Capitalization
$8.01 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
1.68
Who are the company insiders with the largest holdings of BiomX?
Who are the major institutional investors of BiomX?
Which institutional investors are selling BiomX stock?
In the previous quarter, PHGE stock was sold by these institutional investors:
- Nantahala Capital Management LLC
- Ikarian Capital LLC